Leishmania is an obligate intracellular parasite that survives within the phagolysosomes ofits vertebrate hosts' macrophages (1-3). Once the promastigote form ofthe parasite is introduced into the host tissue by a feeding sandfly, it must gain entry into a macrophage in order to survive and develop into the amastigote form. The initial attachment of Leishmania promastigotes to the macrophage is receptor mediated (4-6), however, the identity ofthe ligands on the parasite and their complementary receptors on the surface of the phagocyte is not known. Since some receptors on the macrophage surface initiate a microbicidal response when complexed with their ligand, and others do not (7-9), one possible means by which the parasite may increase its chance of successfully infecting the macrophage is in the "choice" of receptor(s) used during phagocytosis .
Leishmania gp63 (24) 281 tion ofthe particles in ascites fluid (2% in PBS) from two hybridoma cell lines, TueL3.2 and TueL3.9, secreting IgG1 antibodies against different epitopes on gp63. Sheep erythrocytes (E) coated with antibody (EA) or C3bi (EC3bi) were prepared as described previously (17) .
TheAttachment of Ligand-bearing Particles to HumanMO. Monolayers of MO were produced as follows. Cells were suspended at 106/ml in PBS with divalent cations (1 mM CaC12 and 0.5 MM MgC12), 3 mM glucose, and 0.5 mg/ml human serum albumin . The cells were added in 5-pl aliquots to the wells of Terasaki tissue-typing plates and left to settle for 1 h at 37°C. In down-modulation experiments, the Terasaki wells had been previously coated with antibody by incubating the respective wells with 5 ttl of PBS containing 25 pg/ml of the various anti-receptor mAbs for 1 h at 20°C. The monolayer was washed in PBS and rinsed in a final change of DGVB with divalent cations (2 .5 mM veronal buffer, pH 7.5, 75 mM NaCl, 2 .5% dextrose, 0.05 gelatin, 0.15 mM CaC12, and 0.5 MM MgC12) . In experiments involving the use of soluble inhibitors, such as peptides, the inhibitors were introduced to the Terasaki plates at this point, immediately before the addition ofthe ligand-bearing particles .
Attachment of ligand-bearing particles to MO was determined by adding 5 x 104 coated beads or 2 .5 x 105 erythrocytes per well and incubating for 15 or 45 min, respectively at 37°C. The attachment of the particles to the MO was then scored by phase contrast microscopy as detailed previously (17) .
Synthetic FI!ptides. Peptide L10 (LGGALQAGDV), based on residues 402-411 ofthe y chain of human fibrinogen, was synthesized by Peninsula . An inactive analogue of L10, AcLIO, was prepared by acetylating lysine 406 as described (28) . Both L10 and AcL10 were repurified by HPLC on a reverse-phase column . Peptide G15 (GQQHHLGGAKQAGDV) based on residues 398-411 of the y chain of fibrinogen was purchased from Sigma Chemical Co. GRGDSP and GRGDESP were a generous gift from Dr. M. Pierschbacher, La Jolla, CA. Pep63 was synthesized from residues 365-385 of the gp63 amino acid sequence (RLLPGG-LQQGRGDAVGPERGC) by Dr. D. Schlesinger, N.Y.U. Medical Center, NY.
Results
The Binding of gp63 Beads to Human MO. Purified gp63 was incorporated into a phospholipid monolayer supported by 5-pm beads. Fig . 1 illustrates the effect ofincreasing gp63 concentration on the binding of the beads to monolayers of MO. A density of 1.25 x 103 molecules/pmt was sufficient to facilitate the binding of at least one bead to 65 % of the cells . Increasing the ligand density above this level caused a marked increase in the number of beads bound per MO. At a density of 6.35 x 103 molecules/pmz, virtually all the MO had bound multiple beads (at least six beads per cell). All subsequent experiments to identify the MO receptor for gp63 were performed with beads containing 3-7 x 103 molecules/pmt . Phase-contrast microscopical examination of the MO after coincubation with the ligand-bearing beads revealed many gp63 beads bound to the surface of the phagocyte, but none appeared to have been internalized (Fig. 2 A) . In contrast, gp63 beads incubated in IgG against gp63 before addition to the MO monolayers were phagocytosed by the MO (Fig . 2 B) . Internalization of beads was also observed when the other promastigote ligand, LPG, was reconstituted onto the bead surface together with gp63 (data not shown) . We therefore conclude that occupation of the receptor for gp63 is not sufficient stimulus to induce phagocytosis, at least at the ligand densities examined . The addition of another ligand, or a suitable opsonin such as IgG, to the bead surface triggers ingestion. Down-modulation ofReceptors on MO by mAb-coated Surfaces. MO were plated on tissue culture surfaces precoated with mAbs of known specificity. Previous work has shown that surface-bound mAbs cause depletion of target antigens from the accessible, upper portion of the cell plasmalemma (23) . The attachment of gp63 beads was strongly inhibited by plating the MO onto antibodies specific for either the a chain (OKM10) or the R chain (IB4) of CR3 (Fig. 3) . gp63-specific attachment, i.e ., the binding attributable to the ligand on the bead surface, was inhibited by >85% by both these antibodies. In parallel studies, anti-CR3 antibodies mediated a similar inhibition of binding of EC3bi to the MO. Antibodies against the related proteins LFA-1 and p150,95 did not affect attachment of any particle . Similarly, antibodies against the R chain of the VLA family of antigens, which includes the fibronectin receptor, and against HLA molecules, did not affect the attachment of either gp63-or C3bi-bearing particles. None of the absorbed antibodies reduced the binding of antibody-coated gp63 beads, indicating that the reduction in attachment of gp63 beads by anti-CR3 antibodies was caused by depletion of accessible CR3.
The binding of ligand-bearing particles to MO plated onto human serum albumin, IgG, and collagen was also examined . None of these proteins altered the levels of binding of any of the particles. Fibronectin-coated surfaces, on the other hand, caused a small increase in the binding of both EC3bi and gp63 beads (data not shown) in a fashion consistent with previous observations on CR3-mediated attachment (29) . These results indicate that the fibronectin receptor is not involved in the binding of gp63 to the MO surface. Gp63 beads also bound to polymorphonuclear leukocytes . As with the attachment to MO, this binding was mediated by CR3, and could be inhibited by soluble OKM10 antibody (data not shown).
Inhibition ofgp63-mediated Binding to MO by Synthetic Peptides Containing Arg-Gly Asp (R G D) and Related Sequences. CR3 is known to recognize a region of C3bi that contains the triplet Arg-Gly-Asp (R G D) (30) . Since gp63 contains an R G D sequence at amino acid residues 375-377 (31), it is possible that CR3 could recognize this portion ofthe protein . We addressed this question experimentally by examining the effect of a synthetic 21-amino acid peptide, spanning residues 365-386 of the gp63 sequence (see Table II 4 . Competitive inhibition of binding of ligand-bearing beads with synthetic peptides. Monolayers of MO were established and incubated with ligand-bearing beads in the presence of different synthetic peptides . All peptides were added to a final concentration of 2 mg/ml. The peptides that inhibited binding of EC3bi also inhibited the attachment of gp63 beads (Bgp63). These peptides, pep63 and L10, are based on sequences from gp63 and fibrinogen, respectively (see Table II ). None of the other peptides affected the attachment of any of the ligandbearing beads. In addition, the gp63 beads coated with IgG (BIgG) and the beadswithoutligands (Bcon) were also unaffected by the peptides . These results were obtained in three separate experiments each run in duplicate. Inhibition of binding of ligand-bearing beads with synthetic peptides. Monolayes of MO were incubated with either EC3bi or gp63 beads (Bgp63) in the presence of increasing concentrations of synthetic peptides, pep63, and G15 . Both peptides mediated comparable levels of inhibition of the binding of both particles . This graph shows the result from one experiment conducted in triplicate. Similar results were obtained in two independent experiments .
Soluble pep63 effectively inhibited the binding of both gp63 beads and EC3bi to MO (Fig. 4) . Half-maximal inhibition was achieved at til mg/ml (5 x 10-4 M) for both gp63 beads and EC3bi (Fig. 5) . Parallel studies showed that, at the concentrations used, the peptide had no effect on the binding of IgG-coated gp63 beads, thus confirming the specificity ofthe observed inhibition. Moreover, synthetic peptides based on the R G D-containing region of fibronectin (32) failed to affect the binding of either gp63 beads or EC3bi. These data indicate that gp63 contains an amino acid sequence that interacts directly with CR3 . In addition, these results confirm our finding that the fibronectin receptor does not function in the binding of gp63 by MO.
Recent studies have shown CR3 binds not only to the R G D-containing region of C3bi, but also to a related sequence in fibrinogen (Wright, et (Fig. 4) . In contrast, the acetylated form ofthe peptide AcL10, which had previously been shown to be unable to inhibit the binding of EC3bi (Wright, S.D., manuscript in preparation), had no effect on the ability ofeither gp63 beads or EC3bi to bind to MO (Fig. 4) . We used a slightly longer peptide based on the fibrinogen sequence, G15, to demonstrate that the concentration of peptide required to produce effective inhibition of binding was comparable for both EC3bi and gp63 beads (Fig. 5) . These findings further support the conclusion that the inhibition of binding ofgp63 beads by synthetic peptides is due to competition for the complement binding site on CR3 . Half-maximal inhibition of binding occurred at -400 pg/ml of gp63 for both particles. gp63 had no effect on either the negative control, particles with no ligand added (Control), or the positive control, gp63 beads coated with IgG (BIgG). This graph shows the result from one experiment conducted in triplicate . Comparable results were obtained in three independent experiments.
The above data indicate that gp63 contains a sequence that can interact directly with CR3 . To verify that the R G D-containing region is accessible on the native molecule, gp63 was made soluble by removal of the phospholipid anchor known to retain the protein in the membrane (33) . Soluble gp63 competitively inhibited the attachment of both gp63 beads and ofEC3bi to macrophages (Fig. 6 ). Half-maximal inhibition occurred at -400 gg/ml (6.7 x 10-6 M). Thus on a molar basis, intact soluble gp63 is -75-fold more effective than pep63 in inhibiting gp63 bead and EC3bi attachment.
The Effect ofSoluble LPG and pep63 on the Binding and Uptake of Whole Promastigotes and Amastigotes. The attachment and ingestion of whole parasites by human MO in the presence of the promastigote surface antigen LPG and pep63 was examined. The parasites used included L. mexicana promastigotes, from both logarithmic and stationary phase cultures, and amastigotes . Both pep63 and LPG independently suppressed the attachment ofpromastigotes to the MO (Fig. 7) . Simultaneous addition ofboth ligands caused enhanced inhibition, suggesting that the ligands occupy discrete binding sites . Similar results were obtained using L. donovani and L. major promastigotes, indicating that this dual recognition is not species specific (data not shown) . Despite the marked effect these inhibitors had on the attachment of the promastigote stage, the binding ofL. mexicana amastigotes was unaffected . This result demonstrates that the inhibition caused by pep63 and LPG in the promastigote experiments is unlikely to be due to toxicity, and that the amastigote possesses additional or alternative means of binding to and entering phagocytes .
Discussion
The participation of gp63 in the attachment of promastigotes to MO is known from previous studies, both in our own (10) and other laboratories (34) . Since intact promastigotes possess an additional molecule (LPG) that also functions in attachment to MO (11), it has not been possible to dissect the individual contributions ofthese two components . We therefore developed a bead capable ofcarrying a single promastigote ligand, gp63, and studied the interaction between the gp63-bearing particle and the MO surface. In the initial experiments, the binding of gp63 beads to MO was examined as a function of increasing ligand density (Fig. 1) . Maximum binding occurred at ti6-7 x 103 molecules/gm2, a density similar to the theoretical density of the ligand on the promastigote surface (6 x 103 molecules/Pm 2). This was calculated assuming a cell surface area of 80 wm2 and 500,000 copies/cell (35) . mAbs against CR3 have been reported to reduce the binding of Leishmania promastigotes to MO (13) (14) (15) . Since CR3 expresses separate binding sites for both protein (C3bi) and for other ligands, such as bacterial LPS and Histoplasma (36, 37) , the receptor could recognize Leishmania by binding gp63, LPG, or both. To determine if CR3 recognizes gp63, substrate-bound mAbs were used to selectively deplete CR3 from the upper surface of the cell. Such down-modulation of CR3 with either IB4 or OKM10 caused an 85% reduction in the binding of gp63 beads. A comparable inhibition ofbinding ofEC3bi was observed in parallel experiments (Fig.  3 ). These results demonstrate that CR3 is the primary receptor responsible forbinding gp63.
CR3 is a member ofa large family ofstructurally homologous, adhesion-promoting receptors termed "integrins" (38, 39) . This family includes the fibronectin receptor, gpIIb/III of platelets, CR3, and the closely related leukocyte proteins LFA-1 and p150,95. Nearly all integrins bind ligands that contain R G D, or a similar amino acid sequence . For example, CR3 recognizes a region of C3bi that contains the R G D amino acid triplet (30) . Since the deduced amino acid sequence of gp63 was found to contain the triplet R G D at residues 375-377 (31), the existence of which was predicted from immunological data (40), we asked whether this sequence was the target recognized by CR3 . A synthetic peptide comprised of21 amino acids spanning the R G D region of gp63 effectively inhibited the binding of both gp63 beads and EC3bi to MO (Figs. 4 and 5) . Additional experiments demonstrated that peptides previously shown to inhibit the binding of EC3bi to MO were also able to inhibit the attachment of gp63 beads (Table II and Fig. 4) . These results show that gp63 contains a sequence that binds directly to CR3, and that the binding site involved is the same binding site that recognizes C3bi.
To determine ifthe R G D-containing region of gp63 was accessible on the native molecule, we first removed the phospholipid membrane anchor. The resulting soluble gp63 competitively inhibited the attachment of both gp63 beads and EC3bi to MO (Fig. 6) . Interestingly, gp63 was 75-fold more effective than pep63 at mediating inhibition . We assume that gp63 is a more avid ligand for CR3, because the intact protein holds the R G D-containing region in a favorable configuration.
Although gp63 is recognized by CR3, it is not bound by other integrins on the MO surface. Down-modulation of LFA-1, p150,95, or the fibronectin receptor by mAbs did not affect binding ofgp63 beads (Fig. 3) . Plating ofthe cells on fibronectin also failed to decrease binding. Finally, peptides based on the R G D-containing sequence of fibronectin (G R G D S P) did not affect the binding of gp63 beads (Fig. 4) . The data is consonant with previous findings that CR3 does not recognize fibronectin or synthetic peptides based on the fibronectin sequence (30, 41) . The specificity shown by gp63 for CR3 may, in consequence, aid in targetting the promastigote to the MO.
Other investigators have demonstrated that CR3 plays a role in the binding of whole promastigotes to macrophages (13) (14) (15) . To explain the ability of antibodies against CR3 to block parasite binding in the absence of exogenous complement, Blackwell and coworkers (14) have proposed that MO secrete complement components that opsonize the promastigotes. While we cannot rule out a role for autoopsonization under some circumstances, several observations indicate that opsonization does not underlie the binding of gp63 to CR3 described in this study. Strong binding was observed within 15 min, during which time little secretion is likely to occur (42) . Furthermore, we observed strong, anti-CR3-inhibitable binding to PMN, a cell type that has a very low rate of protein synthesis and has not been shown to produce C3. Finally, the binding of gp63 beads and EC3bi was inhibited by soluble gp63 (Fig. 6) , presumably through competition for the same binding site on CR3. We therefore believe that a direct interaction between CR3 and gp63 is sufficient to explain the known CR3 dependence of binding ofLeishmania promastigotes to MO.
Blackwell and colleagues (14) have also observed that Fab fragments from polyclonal anti-C3 antibody blocked the binding of promastigotes to MO and bound to the parasite surface during internalization (14) . Since gp63 and C3bi contain a related amino acid sequence that is recognized by CR3, it is possible that the anti-C3 antibody bound to the R G D region of gp63, not C3 . The existence of a cross-reactive epitope is supported by current results showing that anti-pep63 antibody recognizes both gp63 and the a chain ofC3 (Russell et al., manuscript in preparation) .
Although our experiments demonstrate that CR3 binds gp63, it should be noted that gp63 beads bound by MO were not phagocytosed (Fig. 2) . This finding is consistent with previous observations showing that CR3 on resting MO binds but does not cause internalization of EC3bi (17) . These results indicate that promastigotes require additional, or alternative, ligands that bind to receptors on the MO surface to promote phagocytosis or to enable CR3 to initiate phagocytosis . A previous study has implicated LPG in the attachment of promastigotes to MO (11) . Two observations in the present study support a role for LPG in host cell entry. The addition of LPG to the surface of gp63 beads induced the phagocytes to internalize the particles. Second, binding of promastigotes can be partially inhibited by soluble LPG, and this effect is additive with the inhibitory effect ofpep63 (Fig . 7) . The significance of gp63 and LPG as the principal ligands for MO is highlighted by their extreme abundance on the promastigote surface; 5 x 105 copies of gp63 (35) and 106 copies of LPG (Russell, D. G., unpublished results) .
Leishmania promastigotes have been shown to differentiate in culture from a noninfective form of promastigote in actively dividing cultures, to an infective form in stationary phase cultures (43, 44) . This differentiation is accompanied by changes on the promastigote surface. The surface expression of gp63 is increased (45) , and LPG undergoes some structural modification (46) during the differentiation . Despite these changes, our inhibition experiments conducted with whole promastigotes (Fig. 7) indicate that both infective and noninfective stages use LPG and gp63 to attach to MO. This is consistent with previous observations showing that infectivity was not dependent on the ability of the parasite to bind to, and be internalized by, MO (44) .
These results call into question the exact role of complement in the infection of MO by promastigotes. The predominant form of C3 deposited on the promastigote by serum is Cab, not C3bi (47), thus, raising the possibility that the C3b receptor (CR1) may also participate in the uptake of promastigotes opsonized with complement. Mosser and Edelson (48) have proposed that complement is necessary for the intracellular survival of L. major promastigotes. Our data, however, show that complement is not necessary for the binding ofpromastigotes to MO, and that gp63 binds directly to CR3. The relative contribution of complement, and the endogenous ligands gp63 and LPG, to the infection of MO is currently under study.
Summary
The major surface glycoprotein of Leishmania promastigotes, gp63, was isolated and reconstituted into a lipid membrane immobilized on the surface of 5-pm-diameter silica beads. These beads bound to the macrophage (MO), and the extent ofbinding correlated with the density of gp63 on the bead. The bead thus facilitated analysis ofthe binding specificity of a single ligand, gp63, without contribution from other molecules present on the surface of intact promastigotes . Plating of MO onto substrates coated with antibodies directed against several cell surface receptors indicated that the complement receptor CR3 was necessary for binding gp63.
CR3 recognizes a portion of C3 that contains the sequence R G D. Since gp63 also contains such a sequence, we tested the ability of a synthetic peptide based on the R G D-containing region of gp63 to inhibit the binding of gp63 beads . The R G D-containing peptide from gp63 inhibited the binding of both gp63 beads and EC3bi to MO. Similarly, peptides previously shown to inhibit the binding of C3bi also inhibited the attachment of gp63 beads . The synthetic peptide from the R G D region of gp63 also reduced the binding of intact promastigotes to MO. These results indicate that gp63 binds directly to CR3 .
